Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Co-amoxiclav 500mg/125mg tablets
0501013K0AAAJAJ
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 202,621 |
|
Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free
0501013K0AAAGAG
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 20,212 |
|
Co-amoxiclav 250mg/125mg tablets
0501013K0AAAAAA
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 18,870 |
|
Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free
0501013K0AAADAD
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 6,685 |
|
Co-amoxiclav 125mg/31mg/5ml oral suspension
0501013K0AAAHAH
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 5,897 |
|
Co-amoxiclav 250mg/62mg/5ml oral suspension
0501013K0AAAIAI
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 5,734 |
|
Co-amoxiclav 400mg/57mg/5ml oral suspension sugar free
0501013K0AAAKAK
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 2,669 |
|
Augmentin 625mg tablets
0501013K0BBALAJ
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 1,001 |
|
Co-amoxiclav 400mg/57mg/5ml oral suspension
0501013K0AAAPAP
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 380 |
|
Augmentin 375mg tablets
0501013K0BBAAAA
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 280 |
|
Augmentin 250/62 oral suspension
0501013K0BBANAI
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 89 |
|
Augmentin 125/31 oral suspension
0501013K0BBAPAH
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 40 |
|
Augmentin-Duo 400/57 oral suspension
0501013K0BBAQAP
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 30 |
|
Co-amoxiclav 875mg/125mg tablets
0501013K0AAANAN
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 15 |
|
Co-amoxiclav 500mg/100mg inj vials
0501013K0AAAEAE
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 5 |
|
Co-amoxiclav 1000mg/200mg inj vials
0501013K0AAAFAF
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 4 |
|
Augmentin Intravenous 1.2g inj vials
0501013K0BBAHAF
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 1 |
|
Augmentin Intravenous 600mg inj vials
0501013K0BBACAE
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | 1 |
|
Amiclav 250mg/125mg tablets
0501013K0BCAAAA
|
Amiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Augmentin 375mg dispersible tablets
0501013K0BBABAB
|
Augmentin | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Co-amoxiclav 250mg/125mg dispersible tablets sugar free
0501013K0AAABAB
|
Co-amoxiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Ranclav 125mg/31mg/5ml SF oral suspension
0501013K0BDADAD
|
Ranclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Ranclav 250mg/62mg/5ml SF oral suspension
0501013K0BDACAG
|
Ranclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Ranclav 375mg tablets
0501013K0BDAAAA
|
Ranclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Ranclav 625mg tablets
0501013K0BDABAJ
|
Ranclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.